title: Drug sensitivity profiling and molecular characteristics of cells from pleural effusions of patients with lung adenocarcinoma.
abstract: We propose to assess the therapeutic value of biomarker-guided individualized chemotherapy in patients with metastasizing lung adenocarcinoma. In this study, we used primary cells from pleural effusions from sixteen patients diagnosed with adenocarcinomas originating in the lung and from four patients with no malignant diagnosis. The ex vivo drug sensitivity of primary cells was assessed for 32 chemotherapeutical drugs. Linear regression analyses were performed to examine possible correlations between the drug sensitivity, overall survival and expression of ERCC1 and RRM1. The ex vivo drug sensitivity profiles of the patients revealed considerable heterogeneity in drug response. Vinblastine, vinorelbine, paclitaxel and actinomycin D showed high efficiency against 50% of the tested primary cells. Significant correlation was detected between the ex vivo sensitivity to platinum based drugs and gemcitabine and the level of ERCC1 and RRM1. No significant correlation was however seen between overall survival and drug sensitivity. The heterogeneity of the drug response suggests that optimal care of the adenocarcinoma patients should include the determination of drug sensitivity of the primary cells and would benefit to use personalized therapy.
authors.affiliation: Karolinska Institutet, Department of Laboratory Medicine, Division of Pathology, Karolinska University Hospital, Stockholm, Sweden.|Karolinska Institutet, Department of Microbiology Tumor and Cell Biology (MTC), KI Solna Campus, Karolinska Institutet, Stockholm, Sweden.
authors.forename: Rita
authors.initials: R
authors.lastname: Ötvös
authors.affiliation: Karolinska Institutet, Department of Laboratory Medicine, Division of Pathology, Karolinska University Hospital, Stockholm, Sweden.
authors.forename: Adam
authors.initials: A
authors.lastname: Szulkin
authors.affiliation: Karolinska Institutet, Department of Laboratory Medicine, Division of Pathology, Karolinska University Hospital, Stockholm, Sweden.
authors.forename: Carl-Olof
authors.initials: CO
authors.lastname: Hillerdal
authors.affiliation: Karolinska Institutet, Department of Laboratory Medicine, Division of Pathology, Karolinska University Hospital, Stockholm, Sweden.
authors.forename: Aytekin
authors.initials: A
authors.lastname: Celep
authors.affiliation: Karolinska Institutet, Department of Laboratory Medicine, Division of Pathology, Karolinska University Hospital, Stockholm, Sweden.
authors.forename: Eviane
authors.initials: E
authors.lastname: Yousef-Fadhel
authors.affiliation: Karolinska Institutet, Department of Microbiology Tumor and Cell Biology (MTC), KI Solna Campus, Karolinska Institutet, Stockholm, Sweden.
authors.forename: Henriette
authors.initials: H
authors.lastname: Skribek
authors.affiliation: Karolinska Institutet, Department of Laboratory Medicine, Division of Pathology, Karolinska University Hospital, Stockholm, Sweden.
authors.forename: Anders
authors.initials: A
authors.lastname: Hjerpe
authors.affiliation: Karolinska Institutet, Department of Microbiology Tumor and Cell Biology (MTC), KI Solna Campus, Karolinska Institutet, Stockholm, Sweden.
authors.forename: László
authors.initials: L
authors.lastname: Székely
authors.affiliation: Karolinska Institutet, Department of Laboratory Medicine, Division of Pathology, Karolinska University Hospital, Stockholm, Sweden.
authors.forename: Katalin
authors.initials: K
authors.lastname: Dobra
keywords: ERCC1; Malignant pleural effusions; RRM1; ex vivo chemo-sensitivity assay